Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463

Image: The IW-6463 is an orally administered CNS penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders. Photo: courtesy of yodiyim at FreeDigitalPhotos.net.